Megan Prock McGrath 7/15/26 Megan Prock McGrath 7/15/26

Mighty Therapeutics

Mighty Therapeutics, together with its wholly owned operating subsidiary, Stealth BioTherapeutics Inc., is advancing novel therapies for people living with diseases involving mitochondrial dysfunction.

Megan Prock McGrath 6/8/26 Megan Prock McGrath 6/8/26

Cartesian Therapeutics (NASDAQ: RNAC)

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases.

Megan Prock McGrath 5/14/25 Megan Prock McGrath 5/14/25

Neumora Therapeutics (NASDAQ: NMRA)

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Megan Prock McGrath 1/15/25 Megan Prock McGrath 1/15/25

Umoja Biopharma

Clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.

MacDougall Creative 5/9/24 MacDougall Creative 5/9/24

Werewolf Therapeutics (NASDAQ: HOWL)

Clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer and other immune-mediated conditions.

MacDougall Creative 11/13/23 MacDougall Creative 11/13/23

Acumen Pharmaceuticals (NASDAQ: ABOS)

Clinical-stage drug development company focused on developing novel targeted therapies for Alzheimer's disease.

MacDougall Creative 8/14/23 MacDougall Creative 8/14/23

MindMed (NASDAQ: MNMD)

Clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.

MacDougall Creative 4/25/23 MacDougall Creative 4/25/23

Vedanta Biosciences

A clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia.

MacDougall Creative 3/27/23 MacDougall Creative 3/27/23

Harpoon Therapeutics (NASDAQ: HARP)

Clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

Brad Good 1/4/23 Brad Good 1/4/23

89bio (NASDAQ: ETNB)

Clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

Brad Good 12/22/22 Brad Good 12/22/22

Alto Neuroscience (NYSE: ANRO)

Clinical-stage drug development company pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

Brad Good 12/20/22 Brad Good 12/20/22

OncXerna Therapeutics

Clinical-stage precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates.

Brad Good 11/11/22 Brad Good 11/11/22

Aptinyx (NASDAQ: APTX)

Clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders.

Brad Good 11/10/22 Brad Good 11/10/22

ASLAN Pharmaceuticals (NASDAQ: ASLN)

Clinical-stage immunology focused biopharmaceutical company developing therapies for atopic dermatitis and asthma.

Brad Good 11/9/22 Brad Good 11/9/22

Corbus Pharmaceuticals (NASDAQ: CRBP)

Clinical-stage drug development company pioneering transformative medicines to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.

Brad Good 11/8/22 Brad Good 11/8/22

Elevation Oncology (NASDAQ: ELEV)

Clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers.

Brad Good 11/8/22 Brad Good 11/8/22

Evelo Biosciences (NASDAQ: EVLO)

Clinical-stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects

Brad Good 11/7/22 Brad Good 11/7/22

Inozyme (NASDAQ: INZY)

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization.

Brad Good 11/6/22 Brad Good 11/6/22

Inspirna

Clinical-stage biopharmaceutical company leveraging a proprietary microRNA-based target discovery platform to develop first-in-class small molecule and antibody cancer therapeutics.

Brad Good 11/5/22 Brad Good 11/5/22

Metacrine (NASDAQ: MTCR)

Clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.